updated 12/1/2010 9:15:50 PM ET 2010-12-02T02:15:50

BEIJING, Dec. 1, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the manufacturing license for Kaitong has been issued by the State Food and Drug Administration ("SFDA"). Kaitong is one of the Company's key pipeline candidate products that was in-licensed from the Company's development partner, Jilin Yuhua. The Company continues to expect revenue contribution from the product in early 2011.

Baizhong Xue, the Company's Chairman and CEO, commented, "We are pleased to announce the exciting news that Kaitong has received its manufacturing license as planned. We have already begun to build out our marketing team and sales force in preparation for its launch and are well-prepared to quickly and effectively launch this product across our distribution network. With the addition of Kaitong to our cardiovascular product line, we believe 2011 will be a landmark year for Nuokang. We believe that Kaitong will become, next to Baquting, one of the driving forces behind our future revenue growth." 

The Company will hold a conference call at 8:00 am ET on December 2, 2010 to further discuss the marketing of Kaitong.

United States toll free: 1-866-730-5763
China toll free:  400-8811629
Hong Kong toll free:  800-963844
United Kingdom toll free: 0808-2347616
International: 1-857-350-1587
Conference ID: 85246276

A telephone replay will be available beginning two hours after the conclusion of the call and will be available through December 9, 2010. Listeners may access the replay by dialing:

United States toll free:  1-888-286-8010
International:  1-617-801-6888
Conference ID: 41855787

A webcast will also be available through the Company's website www.nkbp.com. 

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information. 

Safe-Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. Among other things, the statements relating to the Company's expected progress on the new product portfolio may contain forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

CONTACT:  ICR, LLC
          In the U.S.: 
          Ashley M. Ammon
          Christine Duan
            1-646-277-1227
          In China:  
          Wen Lei Zheng
            86-10-6583-7510

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.94%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com